347 related articles for article (PubMed ID: 25899052)
21. Expression and localization of serum resistance associated protein in Trypanosoma brucei rhodesiense.
Milner JD; Hajduk SL
Mol Biochem Parasitol; 1999 Nov; 104(2):271-83. PubMed ID: 10593181
[TBL] [Abstract][Full Text] [Related]
22. The Trypanosoma brucei reference strain TREU927/4 contains T. brucei rhodesiense-specific SRA sequences, but displays a distinct phenotype of relative resistance to human serum.
Vanhamme L; Renauld H; Lecordier L; Poelvoorde P; Van Den Abbeele J; Pays E
Mol Biochem Parasitol; 2004 May; 135(1):39-47. PubMed ID: 15287585
[TBL] [Abstract][Full Text] [Related]
23. Role of expression site switching in the development of resistance to human Trypanosome Lytic Factor-1 in Trypanosoma brucei brucei.
Kieft R; Stephens NA; Capewell P; MacLeod A; Hajduk SL
Mol Biochem Parasitol; 2012 May; 183(1):8-14. PubMed ID: 22226682
[TBL] [Abstract][Full Text] [Related]
24. Detection of Trypanosoma brucei rhodesiense in animals from sleeping sickness foci in East Africa using the serum resistance associated (SRA) gene.
Njiru ZK; Ndung'u K; Matete G; Ndungu JM; Gibson WC
Acta Trop; 2004 May; 90(3):249-54. PubMed ID: 15099811
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of resistance of African trypanosomes to cytotoxic human HDL.
Hager KM; Hajduk SL
Nature; 1997 Feb; 385(6619):823-6. PubMed ID: 9039915
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting.
Lüscher A; de Koning HP; Mäser P
Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174
[TBL] [Abstract][Full Text] [Related]
27. Trypanosome alternative oxidase, a potential therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei subspecies.
Nakamura K; Fujioka S; Fukumoto S; Inoue N; Sakamoto K; Hirata H; Kido Y; Yabu Y; Suzuki T; Watanabe Y; Saimoto H; Akiyama H; Kita K
Parasitol Int; 2010 Dec; 59(4):560-4. PubMed ID: 20688188
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
29.
Cooper A; Ilboudo H; Alibu VP; Ravel S; Enyaru J; Weir W; Noyes H; Capewell P; Camara M; Milet J; Jamonneau V; Camara O; Matovu E; Bucheton B; MacLeod A
Elife; 2017 May; 6():. PubMed ID: 28537557
[TBL] [Abstract][Full Text] [Related]
30. Will the real Trypanosoma brucei rhodesiense please step forward?
Gibson W
Trends Parasitol; 2002 Nov; 18(11):486-90. PubMed ID: 12473364
[TBL] [Abstract][Full Text] [Related]
31. Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1.
Vanwalleghem G; Fontaine F; Lecordier L; Tebabi P; Klewe K; Nolan DP; Yamaryo-Botté Y; Botté C; Kremer A; Burkard GS; Rassow J; Roditi I; Pérez-Morga D; Pays E
Nat Commun; 2015 Aug; 6():8078. PubMed ID: 26307671
[TBL] [Abstract][Full Text] [Related]
32. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill.
Vanhollebeke B; Pays E
Mol Microbiol; 2010 May; 76(4):806-14. PubMed ID: 20398209
[TBL] [Abstract][Full Text] [Related]
33. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis.
Thomson R; Finkelstein A
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2894-9. PubMed ID: 25730870
[TBL] [Abstract][Full Text] [Related]
34. Only the serum-resistant bloodstream forms of Trypanosoma brucei rhodesiense express the serum resistance associated (SRA) protein.
De Greef C; Chimfwembe E; Kihang'a Wabacha J; Bajyana Songa E; Hamers R
Ann Soc Belg Med Trop; 1992; 72 Suppl 1():13-21. PubMed ID: 1417165
[TBL] [Abstract][Full Text] [Related]
35. Conserved sequence of the TgsGP gene in Group 1 Trypanosoma brucei gambiense.
Gibson W; Nemetschke L; Ndung'u J
Infect Genet Evol; 2010 May; 10(4):453-8. PubMed ID: 20302972
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of the Trypanosoma brucei rhodesiense isolates from Tanzania using serum resistance associated gene as molecular marker.
Kibona SN; Picozzi K; Matemba L; Lubega GW
Tanzan Health Res Bull; 2007 Jan; 9(1):25-31. PubMed ID: 17547097
[TBL] [Abstract][Full Text] [Related]
37. Serum resistance-associated protein blocks lysosomal targeting of trypanosome lytic factor in Trypanosoma brucei.
Oli MW; Cotlin LF; Shiflett AM; Hajduk SL
Eukaryot Cell; 2006 Jan; 5(1):132-9. PubMed ID: 16400175
[TBL] [Abstract][Full Text] [Related]
38. De Novo Genome Assembly Shows Genome Wide Similarity between Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.
Sistrom M; Evans B; Benoit J; Balmer O; Aksoy S; Caccone A
PLoS One; 2016; 11(2):e0147660. PubMed ID: 26910229
[TBL] [Abstract][Full Text] [Related]
39. Evolution of the primate trypanolytic factor APOL1.
Thomson R; Genovese G; Canon C; Kovacsics D; Higgins MK; Carrington M; Winkler CA; Kopp J; Rotimi C; Adeyemo A; Doumatey A; Ayodo G; Alper SL; Pollak MR; Friedman DJ; Raper J
Proc Natl Acad Sci U S A; 2014 May; 111(20):E2130-9. PubMed ID: 24808134
[TBL] [Abstract][Full Text] [Related]
40. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
